STEVENSON, Md.--(EON: Enhanced Online News)--Brower Piven, A Professional Corporation, has commenced an investigation of potential securities law violations by ARIAD Pharmaceuticals, Inc. (“ARIAD” or the “Company”) (NasdaqGS: ARIA).
The investigation of ARIAD is related to statements issued by the Company concerning its leukemia drug Iclusig. On October 9, 2013, the Company announced updated data from its PACE trial of Iclusig and revealed that the drug was shown to cause a higher rate of side effects than previously disclosed, that the U.S. Food and Drug Administration had placed a hold on new patient enrollment for Iclusig testing, and that the Company advised patients currently receiving the drug to lower their dosage. The price of ARIAD shares declined significantly following this news.
If you purchased ARIAD common stock between December 14, 2012 and October 9, 2013, the period during which ARIAD common stock may have been overvalued due to possibly misleading statements by the Company, and would like to learn more about the investigation being conducted by Brower Piven, you may email or call Brower Piven, who will, without obligation or cost to you, attempt to answer your questions. You may contact Brower Piven by email at firstname.lastname@example.org, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years.